Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 6, 2026, 3:18 am
Author: Getaka|Social: XLinkedIn

Torrent Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 6, 2026, 3:18 am

Market Cap 1,47,339 Cr.
Current Price 4,353
Intrinsic Value₹4,240.63
High / Low 4,470/3,028
Stock P/E63.9
Book Value 250
Dividend Yield0.74 %
ROCE27.0 %
ROE26.5 %
Face Value 5.00
PEG Ratio2.67

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Torrent Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Torrent Pharmaceuticals Ltd 1,47,339 Cr. 4,353 4,470/3,02863.9 2500.74 %27.0 %26.5 % 5.00
Dr Reddys Laboratories Ltd 1,09,635 Cr. 1,314 1,380/1,02019.7 4320.61 %22.7 %18.0 % 1.00
Cipla Ltd 1,07,189 Cr. 1,326 1,673/1,28222.5 4080.98 %22.7 %17.8 % 2.00
Lupin Ltd 1,06,624 Cr. 2,333 2,362/1,77421.4 4300.51 %21.3 %20.6 % 2.00
Mankind Pharma Ltd 91,907 Cr. 2,226 2,727/2,01252.0 3760.04 %15.0 %13.9 % 1.00
Industry Average20,550.65 Cr1,093.6755.34201.810.38%16.35%15.16%6.10

All Competitor Stocks of Torrent Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 2,4912,4912,5912,6602,7322,7452,8592,8892,8092,9593,1783,3023,303
Expenses 1,7671,7641,8001,8351,8631,8621,9551,9501,8951,9952,1462,2192,215
Operating Profit 7247277918258698839049399149641,0321,0831,088
OPM % 29%29%31%31%32%32%32%32%33%33%32%33%33%
Other Income -1093426553124-1633-42-37-40-23
Interest 10210710391808075645756564845
Depreciation 193196191201213203197198199201201204206
Profit before tax 419433531559631631656661691665738791814
Tax % 30%34%29%31%30%29%30%31%27%25%26%25%22%
Net Profit 292287378386443449457453503498548591635
EPS in Rs 8.638.4811.1711.4113.0913.2713.5013.3814.8614.7116.1917.4618.76

Last Updated: March 3, 2026, 2:10 pm

Below is a detailed analysis of the quarterly data for Torrent Pharmaceuticals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 3,303.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,302.00 Cr. (Sep 2025) to 3,303.00 Cr., marking an increase of 1.00 Cr..
  • For Expenses, as of Dec 2025, the value is 2,215.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,219.00 Cr. (Sep 2025) to 2,215.00 Cr., marking a decrease of 4.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 1,088.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,083.00 Cr. (Sep 2025) to 1,088.00 Cr., marking an increase of 5.00 Cr..
  • For OPM %, as of Dec 2025, the value is 33.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 33.00%.
  • For Other Income, as of Dec 2025, the value is -23.00 Cr.. The value appears strong and on an upward trend. It has increased from -40.00 Cr. (Sep 2025) to -23.00 Cr., marking an increase of 17.00 Cr..
  • For Interest, as of Dec 2025, the value is 45.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 48.00 Cr. (Sep 2025) to 45.00 Cr., marking a decrease of 3.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 206.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 204.00 Cr. (Sep 2025) to 206.00 Cr., marking an increase of 2.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 814.00 Cr.. The value appears strong and on an upward trend. It has increased from 791.00 Cr. (Sep 2025) to 814.00 Cr., marking an increase of 23.00 Cr..
  • For Tax %, as of Dec 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Sep 2025) to 22.00%, marking a decrease of 3.00%.
  • For Net Profit, as of Dec 2025, the value is 635.00 Cr.. The value appears strong and on an upward trend. It has increased from 591.00 Cr. (Sep 2025) to 635.00 Cr., marking an increase of 44.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 18.76. The value appears strong and on an upward trend. It has increased from 17.46 (Sep 2025) to 18.76, marking an increase of 1.30.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 5:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 4,1724,6366,6875,8165,9507,6737,9398,0058,5089,62010,72811,51612,742
Expenses 3,2163,6163,9544,4384,6015,6905,7695,5246,0776,7787,3607,7958,575
Operating Profit 9551,0202,7331,3771,3491,9832,1702,4802,4312,8423,3683,7214,167
OPM % 23%22%41%24%23%26%27%31%29%30%31%32%33%
Other Income 3428632223299-30012157-28845146-1-142
Interest 59175184206308504451353255333354252205
Depreciation 87191238307409618654658662707808795812
Profit before tax 8449402,3431,0889315621,1871,5261,2261,8472,3522,6733,008
Tax % 21%20%26%14%27%22%14%18%37%33%30%28%
Net Profit 6647511,7339346784361,0251,2527771,2451,6561,9112,272
EPS in Rs 19.6222.1951.2227.5920.0412.8930.2836.9922.9736.7948.9456.4767.12
Dividend Payout % 25%25%34%25%35%66%53%47%105%60%57%57%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)13.10%130.76%-46.11%-27.41%-35.69%135.09%22.15%-37.94%60.23%33.01%15.40%
Change in YoY Net Profit Growth (%)0.00%117.66%-176.86%18.70%-8.28%170.78%-112.95%-60.09%98.17%-27.22%-17.61%

Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:10%
5 Years:8%
3 Years:11%
TTM:8%
Compounded Profit Growth
10 Years:10%
5 Years:14%
3 Years:21%
TTM:21%
Stock Price CAGR
10 Years:17%
5 Years:21%
3 Years:34%
1 Year:5%
Return on Equity
10 Years:23%
5 Years:23%
3 Years:24%
Last Year:27%

Last Updated: September 5, 2025, 1:46 pm

Balance Sheet

Last Updated: December 4, 2025, 2:07 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 858585858585858585169169169169
Reserves 1,8182,4063,4094,2664,5384,6404,7395,7535,8686,0296,6877,4218,280
Borrowings 1,1322,7402,3522,5106,4626,0385,7844,8744,0705,3694,0223,2022,822
Other Liabilities 1,9882,5893,0402,7403,1593,3513,4023,3632,8843,0433,6273,6034,244
Total Liabilities 5,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39615,515
Fixed Assets 8752,8332,8593,6887,8557,7487,5337,0656,4238,1218,1387,9477,841
CWIP 5346781,042519647617712889630765361478488
Investments 1862987808044923532181226199173156133
Other Assets 3,4274,0114,2064,5895,2495,3955,7635,9405,6285,5245,8345,8157,053
Total Assets 5,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39615,515

Below is a detailed analysis of the balance sheet data for Torrent Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 169.00 Cr..
  • For Reserves, as of Sep 2025, the value is 8,280.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,421.00 Cr. (Mar 2025) to 8,280.00 Cr., marking an increase of 859.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 2,822.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3,202.00 Cr. (Mar 2025) to 2,822.00 Cr., marking a decrease of 380.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 4,244.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,603.00 Cr. (Mar 2025) to 4,244.00 Cr., marking an increase of 641.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 15,515.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,396.00 Cr. (Mar 2025) to 15,515.00 Cr., marking an increase of 1,119.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 7,841.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,947.00 Cr. (Mar 2025) to 7,841.00 Cr., marking a decrease of 106.00 Cr..
  • For CWIP, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 478.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 10.00 Cr..
  • For Investments, as of Sep 2025, the value is 133.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 133.00 Cr., marking a decrease of 23.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 7,053.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,815.00 Cr. (Mar 2025) to 7,053.00 Cr., marking an increase of 1,238.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 15,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,396.00 Cr. (Mar 2025) to 15,515.00 Cr., marking an increase of 1,119.00 Cr..

Notably, the Reserves (8,280.00 Cr.) exceed the Borrowings (2,822.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5998102,7421,0098941,7981,3932,0051,8032,3683,2662,585
Cash from Investing Activity + -418-2,113-869-798-4,677-246229-444-196-2,335-160-549
Cash from Financing Activity + 861,212-1,435-1933,417-1,314-1,549-1,651-1,78177-2,780-2,298
Net Cash Flow 268-9043718-36623873-89-174110327-262

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow954.00-1.000.00-1.00-5.00-5.00-3.00-2.00-2.00-3.00-1.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 9612579607768766970746359
Inventory Days 297275314318429318362456368298310334
Days Payable 421472523356447345345351250224284239
Cash Conversion Cycle -28-71-1302159429317418814789154
Working Capital Days 2429-128-80-62-52-57-33-277
ROCE %35%27%48%19%13%13%15%17%19%20%23%27%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 71.25%71.25%71.25%71.25%71.25%71.25%71.25%68.31%68.31%68.31%68.31%68.31%
FIIs 12.04%12.85%13.15%14.08%14.14%14.22%14.46%16.17%16.31%16.09%15.92%16.13%
DIIs 8.89%8.22%7.91%7.11%7.15%7.17%6.98%8.25%8.25%8.54%9.17%9.05%
Government 0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%
Public 7.71%7.59%7.59%7.46%7.34%7.25%7.21%7.17%7.02%6.93%6.47%6.41%
No. of Shareholders 63,83161,57269,61269,11771,15474,76579,84885,03586,00581,85678,22676,214

Shareholding Pattern Chart

No. of Shareholders

Torrent Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Large Cap Fund 3,180,904 3.18 1259.89N/AN/AN/A
Axis Large Cap Fund 964,751 1.18 382.12911,3972026-02-23 03:26:155.85%
Franklin India Large Cap Fund 777,862 4 308.1846,6542026-02-23 03:26:15-8.13%
UTI Flexi Cap Fund 686,000 1.15 271.71723,8152026-02-23 03:26:15-5.22%
Canara Robeco Large Cap Fund 407,164 0.94 161.27N/AN/AN/A
SBI Healthcare Opportunities Fund 400,000 4.14 158.43N/AN/AN/A
Axis Large & Mid Cap Fund 387,176 1 153.35N/AN/AN/A
Axis ELSS Tax Saver Fund 337,092 0.41 133.52330,9302026-02-23 02:15:051.86%
HDFC Large and Mid Cap Fund 336,766 0.47 133.39N/AN/AN/A
Nippon India Value Fund 328,626 1.45 130.16353,6262025-11-03 03:03:49-7.07%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 56.4748.9436.7945.9373.98
Diluted EPS (Rs.) 56.4748.9436.7945.9373.98
Cash EPS (Rs.) 79.9672.8257.6785.05112.84
Book Value[Excl.RevalReserv]/Share (Rs.) 224.27202.57183.13351.75344.90
Book Value[Incl.RevalReserv]/Share (Rs.) 224.27202.57183.13351.75344.90
Revenue From Operations / Share (Rs.) 340.25316.96284.23502.72472.97
PBDIT / Share (Rs.) 110.63101.2185.30155.27149.90
PBIT / Share (Rs.) 87.1477.3364.43116.15111.04
PBT / Share (Rs.) 78.9769.4954.5872.4490.18
Net Profit / Share (Rs.) 56.4748.9436.7945.9273.97
NP After MI And SOA / Share (Rs.) 56.4748.9436.7945.9273.97
PBDIT Margin (%) 32.5131.9330.0130.8831.69
PBIT Margin (%) 25.6124.3922.6623.1023.47
PBT Margin (%) 23.2021.9219.2014.4019.06
Net Profit Margin (%) 16.5915.4412.949.1315.63
NP After MI And SOA Margin (%) 16.5915.4412.949.1315.63
Return on Networth / Equity (%) 25.1724.1520.0913.0521.44
Return on Capital Employeed (%) 28.7127.1622.7922.6320.46
Return On Assets (%) 12.7510.998.295.938.89
Long Term Debt / Equity (X) 0.150.230.400.350.50
Total Debt / Equity (X) 0.390.570.850.670.82
Asset Turnover Ratio (%) 0.760.710.680.530.50
Current Ratio (X) 1.191.030.971.201.13
Quick Ratio (X) 0.650.610.560.640.58
Inventory Turnover Ratio (X) 4.780.730.630.680.69
Dividend Payout Ratio (NP) (%) 56.6661.2969.3087.0927.03
Dividend Payout Ratio (CP) (%) 40.0241.1944.2147.0217.72
Earning Retention Ratio (%) 43.3438.7130.7012.9172.97
Cash Earning Retention Ratio (%) 59.9858.8155.7952.9882.28
Interest Coverage Ratio (X) 14.849.698.6610.307.19
Interest Coverage Ratio (Post Tax) (X) 8.675.434.735.954.55
Enterprise Value (Cr.) 111924.9091136.9056758.9950939.2747229.23
EV / Net Operating Revenue (X) 9.728.505.905.995.90
EV / EBITDA (X) 29.8926.6019.6619.3818.62
MarketCap / Net Operating Revenue (X) 9.518.215.415.565.37
Retention Ratios (%) 43.3338.7030.6912.9072.96
Price / BV (X) 14.4212.848.397.957.37
Price / Net Operating Revenue (X) 9.518.215.415.565.37
EarningsYield 0.010.010.020.010.02

After reviewing the key financial ratios for Torrent Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
  • For Cash EPS (Rs.), as of Mar 25, the value is 79.96. This value is within the healthy range. It has increased from 72.82 (Mar 24) to 79.96, marking an increase of 7.14.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.25. It has increased from 316.96 (Mar 24) to 340.25, marking an increase of 23.29.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 110.63. This value is within the healthy range. It has increased from 101.21 (Mar 24) to 110.63, marking an increase of 9.42.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 87.14. This value is within the healthy range. It has increased from 77.33 (Mar 24) to 87.14, marking an increase of 9.81.
  • For PBT / Share (Rs.), as of Mar 25, the value is 78.97. This value is within the healthy range. It has increased from 69.49 (Mar 24) to 78.97, marking an increase of 9.48.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
  • For PBDIT Margin (%), as of Mar 25, the value is 32.51. This value is within the healthy range. It has increased from 31.93 (Mar 24) to 32.51, marking an increase of 0.58.
  • For PBIT Margin (%), as of Mar 25, the value is 25.61. This value exceeds the healthy maximum of 20. It has increased from 24.39 (Mar 24) to 25.61, marking an increase of 1.22.
  • For PBT Margin (%), as of Mar 25, the value is 23.20. This value is within the healthy range. It has increased from 21.92 (Mar 24) to 23.20, marking an increase of 1.28.
  • For Net Profit Margin (%), as of Mar 25, the value is 16.59. This value exceeds the healthy maximum of 10. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.59. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 25.17. This value is within the healthy range. It has increased from 24.15 (Mar 24) to 25.17, marking an increase of 1.02.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.16 (Mar 24) to 28.71, marking an increase of 1.55.
  • For Return On Assets (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has increased from 10.99 (Mar 24) to 12.75, marking an increase of 1.76.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. It has decreased from 0.23 (Mar 24) to 0.15, marking a decrease of 0.08.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.57 (Mar 24) to 0.39, marking a decrease of 0.18.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has increased from 0.71 (Mar 24) to 0.76, marking an increase of 0.05.
  • For Current Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 1.5. It has increased from 1.03 (Mar 24) to 1.19, marking an increase of 0.16.
  • For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.65, marking an increase of 0.04.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.78. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.78, marking an increase of 4.05.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 56.66. This value exceeds the healthy maximum of 50. It has decreased from 61.29 (Mar 24) to 56.66, marking a decrease of 4.63.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 40.02. This value is within the healthy range. It has decreased from 41.19 (Mar 24) to 40.02, marking a decrease of 1.17.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 43.34. This value is within the healthy range. It has increased from 38.71 (Mar 24) to 43.34, marking an increase of 4.63.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 59.98. This value is within the healthy range. It has increased from 58.81 (Mar 24) to 59.98, marking an increase of 1.17.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 9.69 (Mar 24) to 14.84, marking an increase of 5.15.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.67. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 8.67, marking an increase of 3.24.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 111,924.90. It has increased from 91,136.90 (Mar 24) to 111,924.90, marking an increase of 20,788.00.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.72. This value exceeds the healthy maximum of 3. It has increased from 8.50 (Mar 24) to 9.72, marking an increase of 1.22.
  • For EV / EBITDA (X), as of Mar 25, the value is 29.89. This value exceeds the healthy maximum of 15. It has increased from 26.60 (Mar 24) to 29.89, marking an increase of 3.29.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
  • For Retention Ratios (%), as of Mar 25, the value is 43.33. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 43.33, marking an increase of 4.63.
  • For Price / BV (X), as of Mar 25, the value is 14.42. This value exceeds the healthy maximum of 3. It has increased from 12.84 (Mar 24) to 14.42, marking an increase of 1.58.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
  • For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Torrent Pharmaceuticals Ltd as of March 6, 2026 is: ₹3,411.76

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 6, 2026, Torrent Pharmaceuticals Ltd is Overvalued by 21.62% compared to the current share price ₹4,353.00

Intrinsic Value of Torrent Pharmaceuticals Ltd as of March 6, 2026 is: ₹4,227.82

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 6, 2026, Torrent Pharmaceuticals Ltd is Overvalued by 2.88% compared to the current share price ₹4,353.00

Last 5 Year EPS CAGR: 23.92%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.00%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -13.75, which is a positive sign.
  3. The company has higher reserves (5,065.69 cr) compared to borrowings (3,952.08 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (7.38 cr) and profit (253.15 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 61.50, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Torrent Pharmaceuticals Ltd:
    1. Net Profit Margin: 16.59%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 28.71% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 25.17% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 8.67
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.65
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 63.9 (Industry average Stock P/E: 55.34)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.39
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 9682.44 Cr. and Equity Capital is Rs. 169.23 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsTorrent House, Off Ashram Road, Ahmedabad Gujarat 380009Contact not found
Management
NamePosition Held
Mr. Sudhir MehtaChairman Emeritus
Mr. Samir MehtaExecutive Chairman
Mr. Aman Samir MehtaWhole Time Director
Mr. Jinal MehtaNon Executive Director
Mr. Manish Mahendra ChoksiIndependent Director
Mr. Nikhil KhattauIndependent Director
Ms. Ameera ShahIndependent Director
Ms. Nayantara BaliIndependent Director

FAQ

What is the intrinsic value of Torrent Pharmaceuticals Ltd?

Torrent Pharmaceuticals Ltd's intrinsic value (as of 06 March 2026) is ₹4227.82 which is 2.88% lower the current market price of ₹4,353.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,47,339 Cr. market cap, FY2025-2026 high/low of ₹4,470/3,028, reserves of ₹8,280 Cr, and liabilities of ₹15,515 Cr.

What is the Market Cap of Torrent Pharmaceuticals Ltd?

The Market Cap of Torrent Pharmaceuticals Ltd is 1,47,339 Cr..

What is the current Stock Price of Torrent Pharmaceuticals Ltd as on 06 March 2026?

The current stock price of Torrent Pharmaceuticals Ltd as on 06 March 2026 is ₹4,353.

What is the High / Low of Torrent Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Torrent Pharmaceuticals Ltd stocks is ₹4,470/3,028.

What is the Stock P/E of Torrent Pharmaceuticals Ltd?

The Stock P/E of Torrent Pharmaceuticals Ltd is 63.9.

What is the Book Value of Torrent Pharmaceuticals Ltd?

The Book Value of Torrent Pharmaceuticals Ltd is 250.

What is the Dividend Yield of Torrent Pharmaceuticals Ltd?

The Dividend Yield of Torrent Pharmaceuticals Ltd is 0.74 %.

What is the ROCE of Torrent Pharmaceuticals Ltd?

The ROCE of Torrent Pharmaceuticals Ltd is 27.0 %.

What is the ROE of Torrent Pharmaceuticals Ltd?

The ROE of Torrent Pharmaceuticals Ltd is 26.5 %.

What is the Face Value of Torrent Pharmaceuticals Ltd?

The Face Value of Torrent Pharmaceuticals Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Torrent Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports